ADMA Adma Biologics Inc

Price (delayed)

$6.02

Market cap

$1.37B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.13

Enterprise value

$1.45B

ADMA Biologics is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at ...

Highlights
The gross profit has soared by 152% YoY and by 23% from the previous quarter
ADMA's revenue has surged by 68% year-on-year and by 10% since the previous quarter
The EPS has surged by 61% year-on-year but it has declined by 18% since the previous quarter
The company's net income has surged by 57% YoY but it fell by 24% QoQ
ADMA's quick ratio is down by 39% YoY and by 37% QoQ
The equity has declined by 11% year-on-year and by 11% since the previous quarter

Key stats

What are the main financial stats of ADMA
Market
Shares outstanding
228.22M
Market cap
$1.37B
Enterprise value
$1.45B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
10.06
Price to sales (P/S)
5.22
EV/EBIT
N/A
EV/EBITDA
284.02
EV/Sales
5.63
Earnings
Revenue
$258.22M
EBIT
-$3.21M
EBITDA
$5.12M
Free cash flow
$4.03M
Per share
EPS
-$0.13
Free cash flow per share
$0.02
Book value per share
$0.6
Revenue per share
$1.15
TBVPS
$1.45
Balance sheet
Total assets
$329.18M
Total liabilities
$193.98M
Debt
$131.64M
Equity
$135.21M
Working capital
$207.21M
Liquidity
Debt to equity
0.97
Current ratio
5.16
Quick ratio
1.58
Net debt/EBITDA
15.68
Margins
EBITDA margin
2%
Gross margin
34.4%
Net margin
-10.9%
Operating margin
8.4%
Efficiency
Return on assets
-8.3%
Return on equity
-19.5%
Return on invested capital
-0.9%
Return on capital employed
-1.1%
Return on sales
-1.2%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ADMA stock price

How has the Adma Biologics stock price performed over time
Intraday
-3.22%
1 week
-5.79%
1 month
-3.22%
1 year
92.95%
YTD
33.19%
QTD
-8.79%

Financial performance

How have Adma Biologics's revenue and profit performed over time
Revenue
$258.22M
Gross profit
$88.94M
Operating income
$21.63M
Net income
-$28.24M
Gross margin
34.4%
Net margin
-10.9%
Adma Biologics's operating income has surged by 155% YoY
The gross profit has soared by 152% YoY and by 23% from the previous quarter
Adma Biologics's operating margin has surged by 133% YoY
The company's net margin has surged by 75% YoY but it fell by 12% QoQ

Growth

What is Adma Biologics's growth rate over time

Valuation

What is Adma Biologics stock price valuation
P/E
N/A
P/B
10.06
P/S
5.22
EV/EBIT
N/A
EV/EBITDA
284.02
EV/Sales
5.63
The EPS has surged by 61% year-on-year but it has declined by 18% since the previous quarter
The price to book (P/B) is 145% higher than the 5-year quarterly average of 4.1 and 71% higher than the last 4 quarters average of 5.9
The equity has declined by 11% year-on-year and by 11% since the previous quarter
ADMA's revenue has surged by 68% year-on-year and by 10% since the previous quarter
ADMA's price to sales (P/S) is 37% higher than its last 4 quarters average of 3.8 and 2.4% higher than its 5-year quarterly average of 5.1

Efficiency

How efficient is Adma Biologics business performance
The return on sales has surged by 96% year-on-year
The company's return on invested capital has surged by 93% YoY
ADMA's ROE has soared by 63% YoY but it is down by 27% QoQ
The company's return on assets has surged by 60% YoY but it fell by 26% QoQ

Dividends

What is ADMA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ADMA.

Financial health

How did Adma Biologics financials performed over time
Adma Biologics's total assets is 70% more than its total liabilities
ADMA's quick ratio is down by 39% YoY and by 37% QoQ
ADMA's current ratio is down by 25% YoY and by 21% QoQ
The company's debt is 2.6% lower than its equity
The equity has declined by 11% year-on-year and by 11% since the previous quarter
The company's debt fell by 8% YoY and by 8% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.